Vedolizumab 300 mg IV
MLN0002SC-3027
Phase 3 small_molecule completed
Quick answer
Vedolizumab 300 mg IV for Colitis, Ulcerative is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Colitis, Ulcerative
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed